Hematology

AI use is common among U.S. hematology/oncology fellows but formal training is rare

In a multicenter survey of 118 U.S. H/O fellows, 74% reported using AI tools in training or clinical tasks. Only 8% of fellows had received formal AI training despite 92% citing guideline resources like NCCN. Fellows most commonly used LLMs to clarify concepts, summarize literature, and explore emerging research. Reported barriers included concerns about accuracy, data privacy, and lack of ethical or institutional guidance, supporting the need for structured curricula. 1

EBMT proposes a unified framework to define lines of therapy (LoT) across hematologic malignancies

The EBMT consensus defines a LoT as a coherent therapeutic episode given without progression, major toxicity, or treatment failure. A new LoT is triggered by documented progression, relapse, primary refractory disease, or addition of an agent from a distinct therapeutic class. Dose or schedule modifications, planned omissions for toxicity, and bridging therapies to cellular therapy do not create a new LoT. 2

Single-dose melphalan associated with less severe GI and organ toxicity before ASCT in MM

In a propensity-matched cohort of myeloma ASCT patients, single-dose HDM 200 mg/m² had lower severe GI toxicity (19.8% vs 36.6%; OR 0.43). Single-dose conditioning reduced creatinine and transaminase elevations compared with split-dose administration. Apparent faster engraftment with split-dose related to a shorter melphalan-to-infusion interval, not dosing schedule itself. Day+90 responses and long-term outcomes were similar after median 36.5 months follow-up. 3